Sarepta Therapeutics Deal History & Licensing Activity
Sarepta Therapeutics is a large biotech headquartered in US. Over the past three years, Sarepta Therapeutics has been involved in 11 licensing and acquisition transactions, with a primary focus on Oligonucleotides (9 deals). The company currently has 12 active clinical trials, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
12
Top Modality
Oligonucleotides
Focus Area
Rare Disease
Sarepta Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sarepta Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ARO-DM1 | Arrowhead Pharmaceuticals | Oligonucleotides | Unknown | collaboration | May 2026 |
Sarepta Therapeutics Pipeline Focus
Therapeutic areas and modalities where Sarepta Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Sarepta Therapeutics Strategic Signals
Key indicators of Sarepta Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Sarepta Therapeutics Clinical Pipeline
Sarepta Therapeutics has 12 active clinical trials across 4 development phases.
5
Unknown
2
Phase 1
1
Phase 2
4
Phase 3
See How Your Asset Matches Sarepta Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Sarepta Therapeutics Licensing & Deal Activity
Sarepta Therapeutics is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 11 deals over the past three years, Sarepta Therapeutics ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sarepta Therapeutics include Rare Disease (7 deals and trials), Rare Disease (7 deals and trials), Mega Deals (2 deals and trials), and Infectious Disease (2 deals and trials). In terms of modality, Sarepta Therapeutics has shown particular interest in oligonucleotides, other, rnai.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sarepta Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sarepta Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.